The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population

Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research